Related Experiment Videos
Prognostic features of multiple myeloma.
Jesús F San Miguel1, Ramón García-Sanz
1Department of Hematology, University Hospital of Salamanca, Paseo de San Vicente, 58-182, Salamanca 37007, Spain. sanmigiz@usal.es
Best Practice & Research. Clinical Haematology
|July 20, 2005
Summary
Prognostic factors for myeloma patients vary widely, impacting survival. Identifying these factors helps categorize risk and predict individual outcomes for better myeloma management.
Area of Science:
- Hematology
- Oncology
- Medical Research
Background:
- Multiple myeloma (MM) patient outcomes exhibit significant heterogeneity, with survival times varying greatly.
- Accurate prognostication is crucial for risk stratification and personalized patient information.
Purpose of the Study:
- To review the most relevant prognostic factors in multiple myeloma (MM).
- To cover prognostic factors in patients undergoing conventional chemotherapy and high-dose therapy with autologous stem-cell support.
- To include prognostic factors for asymptomatic MM and monoclonal gammopathy of undetermined significance (MGUS) patients.
Main Methods:
- Literature review of prognostic factors in multiple myeloma (MM).
- Analysis of factors in patients receiving conventional chemotherapy.
- Evaluation of factors in patients undergoing high-dose therapy with autologous stem-cell support.
Main Results:
- Prognostic factors have evolved from clinical parameters to include biological, cytogenetic, and molecular markers.
- These markers significantly influence disease outcome in MM patients.
- A comprehensive understanding of these factors aids in risk stratification.
Conclusions:
- Prognostic factors are essential for understanding and managing the heterogeneity of multiple myeloma (MM).
- The continuous identification of new markers refines prognostic accuracy.
- This review consolidates key prognostic information for diverse MM patient groups.